Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The US Food and Drug Administration (FDA) approved the PD-L1 immunohistochemical assay, SP142, as a companion test to determine eligibility for atezolizumab therapy in patients with advanced triple negative breast cancer (TNBC) but data in lung cancer studies suggest the assay suffers from poor reproducibility. We sought to evaluate reproducibility and concordance in PD-L1 scoring across multiple pathologists. Full TNBC sections were stained with SP142 and SP263 assays and interpreted for percentage (%) immune cell (IC) staining by 19 pathologists from 14 academic institutions. Proportion of PD-L1 positive cases (defined as ≥1% IC) was determined for each assay as well as concordance across observers. We utilized a new method we call Observers Needed to Evaluate Subjective Tests (ONEST) to determine the minimum number of evaluators needed to estimate concordance between large numbers of readers, as occurs in the real-world setting. PD-L1 was interpreted as positive with the SP142 assay in an average 58% of cases compared with 78% with SP263 ( p < 0.0001). IC positive continuous scores ranged from 1 to 95% (mean = 20%) and 1 to 90% (mean = 10%) for SP263 and SP142, respectively. With SP142, 26 cases (38%) showed complete two category (<1% vs. ≥1%) concordance; with SP263, 38 cases (50%) showed complete agreement. The intraclass correlation coefficient (ICC) for two category scoring of SP263 and SP142 was 0.513 and 0.560. ONEST plots showed decreasing overall percent agreement (OPA) as observer number increased, reaching a low plateau of 0.46 at ten observers for SP263 and 0.41 at eight observers for SP142. IC scoring with both assays showed poor reproducibility across multiple pathologists with ONEST analysis suggesting more than half of pathologists will disagree about IC scores. This could lead to many patients either receiving atezolizumab when they are unlikely to benefit, or not receiving atezolizumab when they may benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Rimm, D. L., Han, G., Taube, J. M., Yi, E. S., Bridge, J. A., Flieder, D. B., Homer, R., West, W. W., Wu, H., Roden, A. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0013 · Cited by 764 · cited 1×
“This finding is in keeping with prior data showing SP142 to be less sensitive to detect the PD-L1 protein than other assays when evaluated in non-small cell lung carcinomas [4, 5] and by analysis of cell lines [10, 11].”
ResultSelf-citationMukhopadhyay, S., Feldman, M. D., Abels, E., Ashfaq, R., Beltaifa, S., Cacciabeve, N. G., Cathro, H. P., Cheng, L., Cooper, K., Dickey, G. E., et al. (2018) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000948 · Cited by 399
Rugo, H. S., Loi, S., Adams, S., Schmid, P., Schneeweiss, A., Barrios, C. H., Iwata, H., Dieras, V. C., Winer, E. P., Kockx, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.009 · Cited by 116
Cited by
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Self-citationImmunotherapy in breast cancer: an overview of current strategies and perspectives
Debien, V., De Caluwé, A., Wang, X., Piccart-Gebhart, M., Tuohy, V. K., Romano, E., & Buisseret, L. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00508-3 · Cited by 368
Tarantino, P., Viale, G., Press, M. F., Hu, X., Penault-Llorca, F., Bardia, A., Batistatou, A., Burstein, H. J., Carey, L. A., Cortes, J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.008 · Cited by 312
Paver, E. C., Cooper, W. A., Colebatch, A. J., Ferguson, P. M., Hill, S. K., Lum, T., Shin, J.-S., O'Toole, S., Anderson, L., Scolyer, R. A., et al. (2021) · Pathology · doi:10.1016/j.pathol.2020.10.007 · Cited by 242
Shamai, G., Livne, A., Polónia, A., Sabo, E., Cretu, A., Bar-Sela, G., & Kimmel, R. (2022) · Nature Communications · doi:10.1038/s41467-022-34275-9 · Cited by 193
Metadata
- Authors
- Reisenbichler, E. S., Han, G., Bellizzi, A., Bossuyt, V., Brock, J., Cole, K., Fadare, O., Hameed, O., Hanley, K., Harrison, B. T., Kuba, M. G., Ly, A., Miller, D., Podoll, M., Roden, A. C., Singh, K., Sanders, M. A., Wei, S., Wen, H., Pelekanou, V., Yaghoobi, V., Ahmed, F., Pusztai, L., & Rimm, D. L.
- Venue
- Modern Pathology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 33
- Issue
- 9
- Pages
- 1746-1752
- ISSN
- 0893-3952 (ISSN-L)
- OpenAlex
- W3017266548
- Cited by
- 133
- References
- 4
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. https://app.cochat.ai/papers/10.1038/s41379-020-0544-x
- The paper
- Reisenbichler, E. S., Han, G., Bellizzi, A., Bossuyt, V., Brock, J., Cole, K., Fadare, O., Hameed, O., Hanley, K., Harrison, B. T., Kuba, M. G., Ly, A., Miller, D., Podoll, M., Roden, A. C., Singh, K., Sanders, M. A., Wei, S., Wen, H., . . . Rimm, D. L. (2020). Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Modern Pathology. https://doi.org/10.1038/s41379-020-0544-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.